{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:07Z","timestamp":1788865987900,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00198-026-08021-6","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:14:33Z","timestamp":1776233673000},"page":"1145-1156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a multi-center retrospective study"],"prefix":"10.1007","volume":"37","author":[{"given":"Ping-Hsun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Chih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Shan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-8079","authenticated-orcid":false,"given":"Tien-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"7","key":"8021_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"VA Luyckx","year":"2024","unstructured":"Luyckx VA, Tonelli M, Stanifer JW (2024) Chronic kidney disease and the global public health agenda. Nat Rev Nephrol 20(7):473\u2013485","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"8021_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS ONE 11(7):e0158765","journal-title":"PLoS ONE"},{"issue":"1","key":"8021_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04028-z","volume":"26","author":"J Guo","year":"2025","unstructured":"Guo J, Jiao W, Xia S, Xiang X, Zhang Y, Ge X et al (2025) The global, regional, and national patterns of change in the burden of chronic kidney disease from 1990 to 2021. BMC Nephrol 26(1):136","journal-title":"BMC Nephrol"},{"issue":"11","key":"8021_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.124.325488","volume":"136","author":"H Noels","year":"2025","unstructured":"Noels H, van der Vorst EPC, Rubin S, Emmett A, Marx N, Tomaszewski M et al (2025) Renal-cardiac crosstalk in the pathogenesis and progression of heart failure. Circ Res 136(11):1306\u20131334","journal-title":"Circ Res"},{"issue":"5","key":"8021_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","volume":"178","author":"M Madero","year":"2025","unstructured":"Madero M, Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A et al (2025) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving Global Outcomes 2024 Clinical Practice Guideline. Ann Intern Med 178(5):705\u2013713","journal-title":"Ann Intern Med"},{"issue":"9784","key":"8021_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 377(9784):2181\u20132192","journal-title":"The Lancet"},{"issue":"23_suppl_1","key":"8021_CR7","first-page":"III-39","volume":"109","author":"J Davignon","year":"2005","unstructured":"Davignon J (2005) Pleiotropic effects of statins. Circulation 109(23_suppl_1):III-39-III\u221243","journal-title":"Circulation"},{"issue":"4","key":"8021_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3949\/ccjm.69.4.277","volume":"69","author":"IR Reid","year":"2002","unstructured":"Reid IR (2002) Statins and osteoporosis: can these lipid-lowering drugs also strengthen bone? Cleve Clin J Med 69(4):277\u2013288","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"8021_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1210\/jcem.87.4.8412","volume":"87","author":"J Davignon","year":"2002","unstructured":"Davignon J, Laaksonen R (2002) Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87(4):1451\u20131458","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8021_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1359\/jbmr.2003.18.1.88","volume":"18","author":"A Staal","year":"2003","unstructured":"Staal A, Frith JC, French MH, Swartz J, G\u00fcng\u00f6r T, Harrity TW et al (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18(1):88\u201396","journal-title":"J Bone Miner Res"},{"issue":"6","key":"8021_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00776-003-0724-9","volume":"8","author":"H Hatano","year":"2003","unstructured":"Hatano H, Maruo A, Bolander ME, Sarkar G (2003) Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci 8(6):842\u2013848","journal-title":"J Orthop Sci"},{"issue":"5446","key":"8021_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","volume":"286","author":"G Mundy","year":"1999","unstructured":"Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G et al (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446):1946\u20131949","journal-title":"Science"},{"issue":"11","key":"8021_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1055\/s-0028-1082051","volume":"40","author":"H Kaji","year":"2008","unstructured":"Kaji H, Naito J, Inoue Y, Sowa H, Sugimoto T, Chihara K (2008) Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway. Horm Metab Res 40(11):746\u2013751","journal-title":"Horm Metab Res"},{"issue":"1","key":"8021_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.regpep.2010.03.003","volume":"162","author":"M Yamashita","year":"2010","unstructured":"Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y et al (2010) Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK. Akt and Src signaling. Regul Pept 162(1):99\u2013108","journal-title":"Regul Pept"},{"issue":"4","key":"8021_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2020.12.024","volume":"78","author":"M Pazianas","year":"2021","unstructured":"Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease\u2013mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis 78(4):582\u2013589","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"8021_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00198-022-06598-2","volume":"34","author":"MP Duarte","year":"2023","unstructured":"Duarte MP, Ribeiro HS, Neri SGR, Almeida LS, Oliveira JS, Viana JL et al (2023) Prevalence of low bone mineral density (T-score\u2009\u2264 -\u20092.5) in the whole spectrum of chronic kidney disease: a systematic review and meta-analysis. Osteoporos Int 34(3):467\u201377","journal-title":"Osteoporos Int"},{"key":"8021_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186846","author":"CY Hsu","year":"2020","unstructured":"Hsu CY, Chen LR, Chen KH (2020) Osteoporosis in patients with chronic kidney diseases: a systemic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21186846","journal-title":"Int J Mol Sci"},{"issue":"3","key":"8021_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3603","volume":"39","author":"TC Lee","year":"2023","unstructured":"Lee TC, Chen JC, Lin SY, Ho PS, Chen CH, Fu YC et al (2023) Statin use in patients with type 2 diabetes has lower risk of hip fractures: a Taiwan national population-based study. Diabetes Metab Res Rev 39(3):e3603","journal-title":"Diabetes Metab Res Rev"},{"issue":"24","key":"8021_CR19","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1001\/jama.283.24.3205","volume":"283","author":"CR Meier","year":"2000","unstructured":"Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283(24):3205\u20133210","journal-title":"JAMA"},{"issue":"10","key":"8021_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048095","volume":"7","author":"A Helin-Salmivaara","year":"2012","unstructured":"Helin-Salmivaara A, Korhonen MJ, Lehenkari P, Junnila SY, Neuvonen PJ, Ruokoniemi P et al (2012) Statins and hip fracture prevention - a population based cohort study in women. PLoS One 7(10):e48095","journal-title":"PLoS One"},{"issue":"12","key":"8021_CR21","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.jamda.2019.06.027","volume":"20","author":"R Shi","year":"2019","unstructured":"Shi R, Mei Z, Zhang Z, Zhu Z (2019) Effects of statins on relative risk of fractures for older adults: an updated systematic review with meta-analysis. J Am Med Dir Assoc 20(12):1566\u201378.e3","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"8021_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.34172\/apb.2024.051","volume":"14","author":"SM Arabi","year":"2024","unstructured":"Arabi SM, Chambari M, Bahrami LS, Jafari A, Bahari H, Reiner \u017d et al (2024) The effect of statin therapy on bone metabolism markers and mineral density: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Adv Pharm Bull 14(3):591\u2013603","journal-title":"Adv Pharm Bull"},{"issue":"9","key":"8021_CR23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/jbmr\/zjaf077","volume":"40","author":"WD Leslie","year":"2025","unstructured":"Leslie WD, Zarzour F, Binkley N, Morin SN, Schousboe JT (2025) Cross-sectional and longitudinal associations between statin use and bone density: the Manitoba BMD registry. J Bone Miner Res 40(9):1045\u20131051","journal-title":"J Bone Miner Res"},{"issue":"8","key":"8021_CR24","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s11010-022-04621-y","volume":"478","author":"A Svec","year":"2023","unstructured":"Svec A, Adameova A (2023) Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection. Mol Cell Biochem 478(8):1661\u20131667","journal-title":"Mol Cell Biochem"},{"key":"8021_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101152","volume":"16","author":"A Antonenko","year":"2022","unstructured":"Antonenko A, Leahy A, Babenko M, Lyons D (2022) Low dose hydrophilic statins are the preferred agents for females at risk of osteoporosis. Bone Rep 16:101152","journal-title":"Bone Rep"},{"issue":"1","key":"8021_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81628-z","volume":"14","author":"JS Jeong","year":"2024","unstructured":"Jeong JS, Noh Y, Cho SW, Hsieh C-Y, Cho Y, Shin J-Y et al (2024) Association of higher potency statin use with risk of osteoporosis and fractures in patients with stroke in a Korean nationwide cohort study. Sci Rep 14(1):30825","journal-title":"Sci Rep"},{"issue":"15","key":"8021_CR27","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495\u20131504","journal-title":"N Engl J Med"},{"key":"8021_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89\u2013118","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"8021_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80(6):565\u2013581","journal-title":"Clin Pharmacol Ther"},{"key":"8021_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516126","volume":"16","author":"RJ Ludwig","year":"2025","unstructured":"Ludwig RJ, Anson M, Zirpel H, Thaci D, Olbrich H, Bieber K et al (2025) A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol 16:1516126","journal-title":"Front Pharmacol"},{"key":"8021_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CLEP.S145311","volume":"10","author":"TK Lin","year":"2018","unstructured":"Lin TK, Liou YS, Lin CH, Chou P, Jong GP (2018) High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clin Epidemiol 10:159\u2013165","journal-title":"Clin Epidemiol"},{"issue":"3","key":"8021_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.12997\/jla.2021.10.3.322","volume":"10","author":"KJ Kim","year":"2021","unstructured":"Kim KJ, Choi J, Kim JY, Bae JH, Kim KJ, Kim HY et al (2021) Statin therapy and the risk of osteoporotic fractures in patients with metabolic syndrome: a nested case-control study. J Lipid Atheroscler 10(3):322\u2013333","journal-title":"J Lipid Atheroscler"},{"issue":"8","key":"8021_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5551\/jat.RV22006","volume":"30","author":"S Yamada","year":"2023","unstructured":"Yamada S, Nakano T (2023) Role of chronic kidney disease (CKD)-mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD. J Atheroscler Thromb 30(8):835\u2013850","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"8021_CR34","first-page":"52","volume":"28","author":"M Fusaro","year":"2022","unstructured":"Fusaro M, Gallieni M, Rizzo MA (2022) A comprehensive review of CKD-MBD and osteoporosis. Endocrinology and Metabolism Practice 28(1):52\u201358","journal-title":"Endocrinology and Metabolism Practice"},{"issue":"1","key":"8021_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2007.11.004","volume":"14","author":"CY Wang","year":"2008","unstructured":"Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14(1):37\u201344","journal-title":"Trends Mol Med"},{"issue":"3","key":"8021_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nutres.2010.03.004","volume":"30","author":"PY Chen","year":"2010","unstructured":"Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH (2010) Simvastatin promotes osteoblast viability and differentiation via Ras\/Smad\/Erk\/BMP-2 signaling pathway. Nutr Res 30(3):191\u2013199","journal-title":"Nutr Res"},{"key":"8021_CR37","first-page":"5881","volume":"10","author":"IC Tai","year":"2015","unstructured":"Tai IC, Wang YH, Chen CH, Chuang SC, Chang JK, Ho ML (2015) Simvastatin enhances Rho\/actin\/cell rigidity pathway contributing to mesenchymal stem cells\u2019 osteogenic differentiation. Int J Nanomedicine 10:5881\u20135894","journal-title":"Int J Nanomedicine"},{"key":"8021_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042378","author":"MM Granat","year":"2024","unstructured":"Granat MM, Eifler-Zydel J, Kolmas J (2024) Statins-their role in bone tissue metabolism and local applications with different carriers. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25042378","journal-title":"Int J Mol Sci"},{"issue":"3","key":"8021_CR39","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1006\/bbrc.2000.2697","volume":"271","author":"M Sugiyama","year":"2000","unstructured":"Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271(3):688\u2013692","journal-title":"Biochem Biophys Res Commun"},{"key":"8021_CR40","doi-asserted-by":"crossref","unstructured":"Wung C-H, Liu H-Y, Tsai T-T, Chen J-J. Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function. Frontiers in Pharmacology. 2025;Volume 16 - 2025.","DOI":"10.3389\/fphar.2025.1569744"},{"key":"8021_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2025.2548199","author":"R Chikatimalla","year":"2025","unstructured":"Chikatimalla R, Trivedi YV, Ruhela N, Singh S, Lal A, Pawa A et al (2025) Statins and kidney health: exploring cardiovascular benefits, renal protection, and risks in chronic kidney disease. Postgrad Med. https:\/\/doi.org\/10.1080\/00325481.2025.2548199","journal-title":"Postgrad Med"},{"issue":"2","key":"8021_CR42","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Cross JT et al (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 176(2):224\u2013238","journal-title":"Ann Intern Med"},{"issue":"1","key":"8021_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad290","volume":"17","author":"M Fusaro","year":"2024","unstructured":"Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sart\u00f2 GV, Cosmai L et al (2024) Real-world usage of chronic kidney disease \u2013 mineral bone disorder (CKD\u2013MBD) biomarkers in nephrology practices. Clin Kidney J 17(1):sfad290","journal-title":"Clin Kidney J"},{"issue":"8","key":"8021_CR44","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00198-023-06752-4","volume":"34","author":"BSL Riska","year":"2023","unstructured":"Riska BSL, Gunnes N, Stigum H, Finnes TE, Meyer HE, Omsland TK et al (2023) Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS). Osteoporos Int 34(8):1369\u20131379","journal-title":"Osteoporos Int"},{"key":"8021_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.31128\/AJGP-03-22-6365","volume":"52","author":"K Sridharan","year":"2023","unstructured":"Sridharan K (2023) Chronic kidney disease mineral and bone disorder: a guide for general practice. Aust J Gen Pract 52:52\u201357","journal-title":"Aust J Gen Pract"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08021-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08021-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:27Z","timestamp":1788865407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08021-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["8021"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08021-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}